Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
Grant
Overview
Affiliation
Overview
Date/time Interval
March 5, 2014 - September 4, 2014
Awarded By
CHILDREN'S ONCOLOGY GROUP
Total Award Amount
21200.00
Direct Costs
16825.00
Sponsor Award Id
Affiliation
Contributor
Bemrich-Stolz, Christina
Investigator
Friedman M.D., Gregory
Investigator
Hilliard, Lee
Investigator
Howard, Thomas
Investigator
Kutny M.D., Matthew
Investigator
Lebensburger, Jeffrey
Investigator
Whelan M.D., Kimberly
Investigator